Saudi Pharmaceutical Industries Co. (SPIMACO) intrinsic value and dividend analysis using DCF, P/B, PEG and PSG models. Includes dividend yield, payout ratio, and dividend sustainability assessment. Sector: PharmaBiotech & Life Science. Listed on Saudi Exchange Tadawul.
Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) develops, manufactures, and markets pharmaceutical and medicinal products in Saudi Arabia, the Middle East, and North Africa, through its pharmaceutical manufacturing, trading and distribution, and healthcare services segments. It also distributes veterinary and medical equipment products and operates a secondary care hospital. Founded in 1986, the company is headquartered in Buraydah.
TASIV estimates this company's intrinsic value using a Price-to-Book (P/B) model. As of TASIV's most recent data refresh, the estimated intrinsic value is SAR 15.92 compared to a market price of SAR 31.86 (Trading significantly above DCF model value). This is an analytical estimate, not investment advice.
Revenue stayed nearly flat over the three-year period, changing by about 3%, while net income rose steadily, moving from a small loss of about SAR 9.1 million to a profit of roughly SAR 184.4 million. Operating cash flow was far more variable, swinging from a small positive figure to a large negative one and back to a large positive figure. Overall, the company's historical financial performance shows stable revenue, a steady rise in net income, and highly variable operating cash flow.
Over the 5 years on record, dividend per share moved both up and down, from SAR 1.5 to a recent SAR 0.6, with a low of SAR 0.5 and a high of SAR 1.5 along the way. Payments have been made on an Annual basis throughout this period. The company's dividend history shows no consistent year-over-year direction. Current dividend yield is approximately 1.88%, with a payout ratio of approximately 39.05%.
TASIV's Competitive Advantage assessment for this company is Moderate (51/100), based on profitability, predictability, financial strength, and growth resilience.
Based on TASIV's Price-to-Book (P/B) model, the estimated intrinsic value of Saudi Pharmaceutical Industries Co. (SPIMACO) is approximately SAR 15.92, compared to a current market price of SAR 31.86. This is an analytical estimate based on the company's financial data, not investment advice or a recommendation to buy or sell.
According to TASIV's model, Saudi Pharmaceutical Industries Co. (SPIMACO) is currently "Trading significantly above DCF model value".
Saudi Pharmaceutical Industries Co. (SPIMACO)'s dividend yield is approximately 1.88%, with a payout ratio of approximately 39.05%, based on TASIV's most recent verified data.
Loading 2070...